Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Total Non-Current Liabilities (2016 - 2025)

Traws Pharma (TRAW) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 20.94% year-over-year to $11.1 million; the TTM value through Dec 2025 reached $11.1 million, down 20.94%, while the annual FY2025 figure was $11.1 million, 20.94% down from the prior year.
  • Total Non-Current Liabilities hit $11.1 million in Q4 2025 for Traws Pharma, up from $7.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $14.1 million in Q4 2024 and bottomed at $7.4 million in Q2 2025.
  • Average Total Non-Current Liabilities over 3 years is $10.8 million, with a median of $11.1 million recorded in 2021.
  • Year-over-year, Total Non-Current Liabilities rose 4.84% in 2021 and then fell 20.94% in 2025.
  • Traws Pharma's Total Non-Current Liabilities stood at $10.9 million in 2021, then rose by 29.88% to $14.1 million in 2024, then dropped by 20.94% to $11.1 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $11.1 million, $7.9 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.